In accordance with 37 C.F.R. § 1.121(c) (3), please substitute for pending claims 16, 18-19, 47, and 52-57 with the following clean version of the claims. The changes to these claims are shown explicitly in the attached "Marked Up Version of Claims."

16. (Amended) A pharmaceutical composition comprising at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one C-terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses, wherein the fusion protein contains no papillomavirus-unspecific epitopes and wherein the pharmaceutical composition is capable of preventing or treating human papillomavirus (HPV)-specific tumour.

18. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant.

19. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition comprises suitable additives and/or excipients.

47. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant and the L1 protein is a deleted L1 protein.

52. (Amended) The pharmaceutical composition according to claim 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.

53. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant.

54. (Amended) The pharmaceutical composition according to claim 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45.

55. (Amended) The pharmaceutical composition according to claim 20, wherein the salt is an alkali metal or alkaline earth metal salt.

56. (Amended) The pharmaceutical composition according to claim 20, wherein the pH is adjusted using a buffer.

57. (Amended) The pharmaceutical composition according to claim 30 in the form of a combination vaccine, wherein the papillomaviruses are selected from HPV-16 and HPV-18 or HPV-18, HPV-31, HPV-45 and HPV-58 or HPV-6 and HPV-11.

Please add the following new claims 58-62:

58. (New) The pharmaceutical composition according to claim 30, wherein the HPV is selected from HPV-6, HPV-11, HPV-16, HPV-31, HPV-33, HPV-35, HPV-42, HPV-52, and/or HPV-58.

59. (New) The pharmaceutical composition according to claim 58, wherein the HPV is HPV-16.

60. (New) A method for producing a pharmaceutical composition comprising combining at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one C-terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses, wherein the fusion protein contains no papillomavirus-unspecific epitopes, together with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition, said pharmaceutical composition being capable of preventing or treating human papillomavirus (HPV)-specific tumour.

61. (New) A method for preventing or treating human papillomavirus (HPV)-specific tumour, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 16.

62. (New) The pharmaceutical composition according to claim 51, wherein the HPV is selected from HPV-6, HPV-11, HPV-16, HPV-31, HPV-33, HPV-35, HPV-42, HPV-52, and/or HPV-58.--